News

Goal of Gaucher Awareness Month 2025? A shorter diagnostic journey.

International Gaucher’s Day on Oct. 1 kicks off Gaucher’s Awareness Month, with patients, families, advocates, and medical professionals coming together to increase understanding and support for those living with Gaucher disease. The 2025 campaign theme, sponsored by the International Gaucher Alliance (IGA), is “See the Signs, Shorten the Diagnostic…

Measuring lyso-Gb1 levels may aid diagnosis accuracy in Gaucher

Measuring levels of lyso-Gb1, a fatty molecule often used as a biomarker of Gaucher disease (GD) severity, could help improve the accuracy of diagnostic tests for the rare condition, according to a new report from a South American research team. While low activity of the glucocerebrosidase (GCase) enzyme is…

Obesity may affect SRT treatment response in Gaucher disease

A 31-year-old woman with type 1 Gaucher disease (GD) experienced worsening symptoms and rising disease activity markers after switching from long-term enzyme replacement therapy (ERT) to Cerdelga (eliglustat), according to a recent case report. The woman — who was obese and had her spleen surgically removed years…

Fatty molecule may cause nerve cell damage in Gaucher: Study

In Gaucher disease, the toxic buildup of a fatty molecule called glucosylsphingosine (lyso-Gb1) leads to issues with how nerve cells generate energy and other cellular problems, according to a new study. Lyso-Gb1 is a biomarker of disease burden and response to treatment. The findings help to understand how the…

Anti-inflammatory drugs treat lung issues in baby with Gaucher disease

Treatment with corticosteroids and hydroxychloroquine to dampen inflammation helped ease serious lung problems in an infant with type 3 Gaucher disease, a case report shows. The child developed breathing difficulties and low blood oxygen despite being diagnosed early and starting enzyme replacement therapy (ERT). Because doctors suspected inflammation…

Why do some Gaucher patients face Parkinson’s disease risk?

Differences in nerve cell function may explain why some people with Gaucher disease develop the neurodegenerative Parkinson’s disease and others do not, a study found. When researchers compared nerve cells derived from siblings with Gaucher with different outcomes — one developed Parkinson’s while the other did not — they found…

Sharp gearing up to move Gaucher disease treatment ‘901 to trial

Sharp Therapeutics is gearing up to ask the U.S. Food and Drug Administration (FDA) for permission to begin testing its Gaucher disease treatment candidate ‘901 in clinical trials. The developer, a preclinical-stage biotechnology company, announced that it’s engaged the contract research organization Rho to help it put together its…